Activin and Inhibin

Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K i s of 0.561 and 2.98 nM for free human FXa and prothrombinase . Edoxaban tosylate exhibits more than 10,000-fold selectivity over

EEDi-5285 is an exceptionally potent and orally active embryonic ectoderm development (EED) inhibitor with an IC 50 value of 0.2 nM for binds to the EED protein. EEDi-5285 has anti-cancer activityIn VitroEEDi-5285 inhibits cell growth with IC 50

EEDi-5285 is an exceptionally potent and orally active embryonic ectoderm development (EED) inhibitor with an IC 50 value of 0.2 nM for binds to the EED protein. EEDi-5285 has anti-cancer activityIn VitroEEDi-5285 inhibits cell growth with IC 50

EFdA-TP tetraammonium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetraammonium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetraammonium inhibits HIV-1 RT

EFdA-TP tetraammonium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetraammonium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetraammonium inhibits HIV-1 RT

Efflux inhibitor-1 (compound 2) is a pyrazolo[1,5-a]pyrimidine efflux inhibitor. Efflux inhibitor-1 selectively targets toward ABCG2/BCRP over ABCB1 with IC 50 s of 0.45 μM and 2.17 μM, respectivelyForm:SolidIC50&amp: Target:IC50: 0.45 μM

Efflux inhibitor-1 (compound 2) is a pyrazolo[1,5-a]pyrimidine efflux inhibitor. Efflux inhibitor-1 selectively targets toward ABCG2/BCRP over ABCB1 with IC 50 s of 0.45 μM and 2.17 μM, respectivelyForm:SolidIC50&amp: Target:IC50: 0.45 μM

Efflux inhibitor-1 (compound 2) is a pyrazolo[1,5-a]pyrimidine efflux inhibitor. Efflux inhibitor-1 selectively targets toward ABCG2/BCRP over ABCB1 with IC 50 s of 0.45 μM and 2.17 μM, respectivelyForm:SolidIC50&amp: Target:IC50: 0.45 μM

Efflux inhibitor-1 (compound 2) is a pyrazolo[1,5-a]pyrimidine efflux inhibitor. Efflux inhibitor-1 selectively targets toward ABCG2/BCRP over ABCB1 with IC 50 s of 0.45 μM and 2.17 μM, respectivelyIC50&amp: Target:IC50: 0.45 μM (ABCG2/BCRP), 2.17

EHMT2-IN-1 is a potent EHMT inhibitor, with IC 50 s of all &lt:100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disorder or cancerIn VitroEHMT2-IN-1 (Compound 108) potent EHMT inhibitor, with IC 50 s of all

EHMT2-IN-1 is a potent EHMT inhibitor, with IC 50 s of all &lt:100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disorder or cancerIn VitroEHMT2-IN-1 (Compound 108) potent EHMT inhibitor, with IC 50 s of all

EHMT2-IN-1 is a potent EHMT inhibitor, with IC 50 s of all &lt:100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2. Used in the research of blood disorder or cancerIn VitroEHMT2-IN-1 (Compound 108) potent EHMT inhibitor, with IC 50 s of all